RealPatient

Tisa-cel has shown efficacy in a broad range of DLBCL patients

Relapsed or refractory patients following 2 lines of therapy1–4

Ineligible or not a candidate for ASCT

Transplant-intended, yet haven’t responded to salvage chemo

Relapsed post
ASCT

Refractory disease

High grade lymphoma

  • References: 1. Kymriah [summary of product characteristics]. Nuremberg, Germany: Novartis Pharma GmbH; 2022.
  • 2. Schuster SJ et al. N Engl J Med. 2019;380(1):45–56.
  • 3. Landsburg DJ et al. American Society of Hematology Annual Meeting, 11–14 December 2021, Atlanta, GA. Abstract 429.
  • 4. Landsburg DJ et al. American Society of Hematology Annual Meeting, 10–13 December 2022, New Orleans, LA. Presentation 656.

Would you consider using Tisa-cel in different patient types?

Based on our discussion today, how likely would you be to prescribe tisa-cel for your next similar R/R DLBCL patient